PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses
G Lambrecht, T Friebe, U Grimm, U Windscheif… - European journal of …, 1992 - Elsevier
G Lambrecht, T Friebe, U Grimm, U Windscheif, E Bungardt, C Hildebrandt, HG Bäumert…
European journal of pharmacology, 1992•ElsevierWe have characterized PPADS (pyridoxalphosphate-6-azophenyl-2′, 4′-disulfonic acid)
as a novel antagonist which selectively blocks P 2 purinoceptor-mediated responses in
rabbit vas deferens at pre-and postjunctional sites. PPADS did not interact with α 1-
adrenoceptors, muscarinic M 2 and M 3 receptors, histamine H 1 and adenosine A 1
receptors. Thus, PPADS is a novel and useful pharmacological tool to study co-transmission
in tissues where ATP and co-existing neurotransmitters act in concert.
as a novel antagonist which selectively blocks P 2 purinoceptor-mediated responses in
rabbit vas deferens at pre-and postjunctional sites. PPADS did not interact with α 1-
adrenoceptors, muscarinic M 2 and M 3 receptors, histamine H 1 and adenosine A 1
receptors. Thus, PPADS is a novel and useful pharmacological tool to study co-transmission
in tissues where ATP and co-existing neurotransmitters act in concert.
Abstract
We have characterized PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid) as a novel antagonist which selectively blocks P2 purinoceptor-mediated responses in rabbit vas deferens at pre- and postjunctional sites. PPADS did not interact with α1-adrenoceptors, muscarinic M2 and M3 receptors, histamine H1 and adenosine A1 receptors. Thus, PPADS is a novel and useful pharmacological tool to study co-transmission in tissues where ATP and co-existing neurotransmitters act in concert.
Elsevier
